Targeting epigenetic regulators for cancer therapy

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Biology

Background:

• Human gene expression is regulated by epigenetic factors like histone methyltransferases and chromatin remodelers.
• Dysregulation of epigenetic pathways can cause widespread gene expression changes and diseases.
• Genomic alterations interacting with epigenomic factors are implicated in hematologic and solid tumors.

Purpose of the Study:

• To identify epigenetic regulators contributing to oncogenesis.
• To develop drugs targeting aberrant epigenetic regulators.
• To explore the role of epigenetic factors in normal and cancer cells.

Main Methods:

• Translational research to identify key epigenetic regulators.
• Development of small-molecule inhibitors for specific epigenetic targets.
• Preclinical and clinical studies to evaluate therapeutic potential.

Main Results:

• Identification of histone methyltransferases (DOT1L, EZH2) and BET family proteins as key oncogenic drivers.
• Demonstration of therapeutic value of small-molecule inhibitors in preclinical and clinical settings.
• Validation of epigenetic inhibitors for further functional studies.

Conclusions:

• Epigenetic regulators are crucial in cancer development.
• Targeting aberrant epigenetic pathways with inhibitors offers a promising therapeutic strategy.
• Further research using these inhibitors will elucidate epigenetic factor functions in health and disease.